The stock of Reviva Pharmaceuticals Holdings Inc (RVPH) has seen a 14.47% increase in the past week, with a 42.51% gain in the past month, and a -3.33% decrease in the past quarter. The volatility ratio for the week is 9.75%, and the volatility levels for the past 30 days are at 13.29% for RVPH. The simple moving average for the last 20 days is 11.18% for RVPH stock, with a simple moving average of -27.87% for the last 200 days.
Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) Right Now?
The 36-month beta value for RVPH is also noteworthy at -0.02. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RVPH is 28.50M, and at present, short sellers hold a 22.57% of that float. The average trading volume of RVPH on December 05, 2024 was 452.09K shares.
RVPH) stock’s latest price update
The stock price of Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has surged by 4.40 when compared to previous closing price of 1.25, but the company has seen a 14.47% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-14 that – 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended September 30, 2024 and summarized recent business highlights.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at 8.90% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.98% of loss for the given period.
Volatility was left at 13.29%, however, over the last 30 days, the volatility rate increased by 9.75%, as shares surge +36.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.19% lower at present.
During the last 5 trading sessions, RVPH rose by +11.82%, which changed the moving average for the period of 200-days by -70.01% in comparison to the 20-day moving average, which settled at $1.1723. In addition, Reviva Pharmaceuticals Holdings Inc saw -74.66% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RVPH
The total capital return value is set at 3.48. Equity return is now at value -1806.28, with -512.93 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc (RVPH), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -401.44. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is 5205.61.
Currently, EBITDA for the company is -39.5 trillion with net debt to EBITDA at 0.22. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.39.
Conclusion
In summary, Reviva Pharmaceuticals Holdings Inc (RVPH) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
